ArticleBMC ophthalmology2026
Ocular changes in patients on Topiramate therapy: a hospital-based comparative study.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the effect of newly administered Topiramate therapy on various ophthalmological parameters.
methodsThis was a hospital-based, prospective, non-randomized, longitudinal, comparative study conducted in the Department of Ophthalmology at a tertiary care hospital from August 2024 to March 2025. Patients aged between 18 and 40 years, and newly initiated on Topiramate therapy by the department of Neurology, were recruited in the study and constituted the study group. Age- and gender-matched healthy individuals constituted the control group. A comprehensive ophthalmic evaluation was done in every case. Ocular parameters studied were intraocular pressure (IOP), central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT), and peripapillary retinal nerve fiber layer (RNFL) thickness. Assessment was performed at baseline and at 15 days, 1 month, and 3 months following Topiramate therapy.
resultsA total of 160 eyes of 80 patients (40 patients newly initiated on Topiramate therapy and 40 healthy controls) were analyzed in the study. The mean age was 30.27 ± 4.83 years and 30.7 ± 4.6 years, respectively, in both groups. Significant increases were observed in IOP (from 13.46 ± 1.71 mm Hg to 18.18 ± 2.48 mm Hg, P < 0.001), CCT (from 516.76 ± 34.58 μm to 524.38 ± 36.04 μm, P < 0.001), LT (from 3.81 ± 0.33 mm to 3.85 ± 0.33 mm, P < 0.001), and peripapillary RNFL thickness (P < 0.001 in all quadrants). ACD showed a significant reduction over time (P < 0.001), and a progressive myopic shift was noted (-0.20 ± 0.39 D to -0.37 ± 0.33 D, P < 0.001).
conclusionThe findings of the present study highlight the need for routine ophthalmic evaluations in patients on Topiramate to detect early changes and prevent vision-threatening complications. Given the progressive nature of these alterations, early intervention and close monitoring are crucial for patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.